Biological
ELAD
ELAD is a biological therapy with 5 clinical trials. Historical success rate of 33.3%.
Total Trials
5
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
33.3%
Based on 1 completed trials
Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
200%(2 trials)
Terminated
2(40%)
Phase Distribution
Ph phase_2
3
60%
Ph phase_3
1
20%
Phase Distribution
0
Early Stage
3
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
3(75.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
25.0%
1 of 4 finished
Non-Completion Rate
75.0%
3 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(1)
Terminated(3)
Other(1)
Detailed Status
Terminated2
Withdrawn1
unknown1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
33.3%
Most Advanced
Phase 3
Trials by Phase
Phase 23 (75.0%)
Phase 31 (25.0%)
Trials by Status
withdrawn120%
unknown120%
completed120%
terminated240%
Recent Activity
0 active trials
Showing 5 of 5
terminatedphase_3
To Assess Safety/Efficacy of ELAD in Subjects w/ Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure
NCT01829347
terminatedphase_2
Safety and Efficacy of the ELAD System (ELAD) to Treat Acute Liver Failure (ALF)
NCT01875874
unknown
Use of the ELAD® in Patients With Liver Failure to Provide Expanded Access With Cost Recovery
NCT00832273
completedphase_2
Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure
NCT00030225
withdrawnphase_2
Safety and Efficacy of the Extracorporeal Liver Assist Device (ELAD®) In Patients With Fulminant Hepatic Failure (FHF)
NCT00832728
Clinical Trials (5)
Showing 5 of 5 trials
NCT01829347Phase 3
To Assess Safety/Efficacy of ELAD in Subjects w/ Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure
NCT01875874Phase 2
Safety and Efficacy of the ELAD System (ELAD) to Treat Acute Liver Failure (ALF)
NCT00832273
Use of the ELAD® in Patients With Liver Failure to Provide Expanded Access With Cost Recovery
NCT00030225Phase 2
Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure
NCT00832728Phase 2
Safety and Efficacy of the Extracorporeal Liver Assist Device (ELAD®) In Patients With Fulminant Hepatic Failure (FHF)
All 5 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 5